PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31587744-9	2019	Results also demonstrated a possible relationship between less opioid consumption in patients receiving a PAI of liposomal bupivacaine (P = .037).	Bupivacaine	123-134	serpin family E member 1	Homo sapiens	106-109	
28844768-4	2018	The purpose of this study was to determine the safety and pharmacokinetics of bilateral full-dose PAI liposomal bupivacaine in the blood collected in patients undergoing simultaneous bTKA.	Bupivacaine	112-123	serpin family E member 1	Homo sapiens	98-101	
28844768-14	2018	CONCLUSION: The use of full-dose PAI with liposomal bupivacaine placed into each knee during simultaneous bTKA is safe with systemic bupivacaine levels well below reported cardiac and neurotoxic levels.	Bupivacaine	52-63	serpin family E member 1	Homo sapiens	33-36	
28844768-14	2018	CONCLUSION: The use of full-dose PAI with liposomal bupivacaine placed into each knee during simultaneous bTKA is safe with systemic bupivacaine levels well below reported cardiac and neurotoxic levels.	Bupivacaine	133-144	serpin family E member 1	Homo sapiens	33-36